Company news

Kyowa Kirin Co., Ltd. news in 2026

Kyowa Kirin Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

October 12, 2026

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

September 29, 2026

Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans

August 31, 2026

Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 Semi Annual

August 3, 2026

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union

July 21, 2026

FDA Selects Kyowa Kirin for PreCheck Pilot Program to Accelerate Manufacturing Timelines and Enhance Supply Chain Resilience

June 30, 2026

New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome

June 29, 2026

Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL

June 10, 2026

FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH

May 14, 2026

Kyowa Kirin: Consolidated Financial Summary (IFRS) Fiscal 2026 First Quarter

May 7, 2026

Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 First Quarter

May 7, 2026

Results Presentation Fiscal 2026 First Quarter

May 7, 2026

CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

May 6, 2026

Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA

April 30, 2026

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

April 24, 2026

(Correction / Correction of Numerical Data) Partial Correction of "Consolidated Financial Summary Fiscal 2025"

March 9, 2026

Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials

March 3, 2026

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands

March 2, 2026

Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data

February 27, 2026

Announcement regarding the Partial amendments to the Articles of Incorporation (0B)

February 19, 2026

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program

February 9, 2026

Kyowa Kirin Announces Changes in Directors and Management Structure

February 9, 2026

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

January 30, 2026

Decks in 2026